Rob Abbott – CEO, ISPOR
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
ABBOTT LABORATORIES is an American-based, global, diversified healthcare firm. Among the world’s largest and most successful corporations, ABBOTT has a presence in more than 160 countries.
Cardiovascular
Diabetes
Diagnostics
Nutrition
Neuromodulation
Pharmaceuticals
Contact:
Address: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064
Tel: (224) 667-6100
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just…
Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
Regular PharmaBoardroom contributor David H. Crean outlines the resilient and cautious optimism observed at JPM 2025, the annual healthcare financing conference held near San Francisco’s Union Square. While uncertainties and…
Drawing on insights from DIA’s 2024 Global Annual Meeting, Martin Hodosi and Rosanna Lim of Kearney Healthcare and Life Sciences examine some of the key ethical challenges around integrating AI…
In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain…
While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the…
With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick…
The Biosecure Act has been excluded from a recent key defense spending bill, leaving its future unclear. But whether or not it ends up being passed, the legislation has already…
For those concerned that opinion and not science may determine US public health policy under president-elect Trump, the choice of surgeon Martin Makary as head of the FDA may be…
Scott D. Ramsey of the Fred Hutchinson Cancer Center discusses the trend driving pharmaceutical companies to reorganize or eliminate their health economics and outcomes research (HEOR) groups. The original version…
With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk…
As Donald Trump assembles his new government, speculations about the consequences of his second presidential term abound. For the life sciences industry, the US president-elect’s more business-friendly stances could entail…
Aitia Bio’s Colin Hill, writing in the November 2024 issue of DIA’s Global Forum magazine outlines why “digital twins” – virtual models of patients, systems, or devices that simulate real-world…
Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of…
See our Cookie Privacy Policy Here
